ERBB2 and breast carcinoma: In addition, intratumor heterogeneity of HER2 gene amplification has been observed in breast cancer, ranging from a few [15] to up to 36 % of the amplified cases [16], which introduces additional difficulties in HER2 status evaluation especially for equivocal cases [17]